sar443579
sanofi
['aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)', 'leusm', 'mds']
#asco23 #leusm #mdssm patel: outcomes are poor for aml pts after ven failure, so we need more options. several cd123 targeted agents under investigation (nice summary slide). sar443579 cd123 nk engager has &lt;20% cr rate but is well tolerated, allowing exploration of higher doses. 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)